BioTuesdays

Cantor cuts Otonomy PT to $6 from $13

Cantor Fitzgerald slashed its price target for Otonomy (NASDAQ:OTIC) to $6 from $13 but maintained its “overweight” rating, after the company announced that the Phase 3 study of OTIVIDEX in Ménière’s disease did not...

Evolus

Cantor ups Evolus PT to $20 from $11

Cantor Fitzgerald raised its price target for Evolus (NASDAQ:EOLS) to $20 from $11, following a litigation settlement, which Cantor believes “increases earnings visibility for Evolus, and removes a large overhang on the...

Reshape-Lifesciences-Logo

AGP starts ReShape Lifesciences at buy; PT $12

Alliance Global Partners initiated coverage of ReShape Lifesciences (OTCQB:RSLS) with a “buy” rating and price target of $12. The stock was quoted at $7.54 in afternoon trading on Feb. 18. ReShape is a rare pure-play in...

Titan Pharmaceuticals Logo

Maxim ups Titan Pharma to buy from hold; PT $11

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold” with a new price target of $11, citing multiple strategy, management, cap-structure and financing changes at Titan, which should position the...

Hepion Pharmaceuticals

Hepion Pharma closes $88.4-million offering

Hepion Pharmaceuticals (NASDAQ:HEPA) closed a public offering of 44.2 million common shares at a price of $2 each for gross proceeds of $88.4-million. After deducting underwriting fees and other offering expenses, net...

Artelo Biosciences Logo

Maxim ups Artelo Biosciences PT to $5 from $3

Maxim Group raised its price target for Artelo Biosciences (NASDAQ:ARTL) to $5 from $3, citing rising valuations across the cannabinoid and cannabis space, and as Artelo begins to map out its path forward as a cancer...

HEXO to acquire Zenabis Global

HEXO (TSX, NYSE:HEXO) agreed to acquire Zenabis Global (TSX:ZENA) by way of a court-approved plan of arrangement under the Business Corporations Act of British Columbia, in an all-share transaction valued at...

Amryt-Logo

SVB Leerink starts Amryt Pharma at OP; PT $40

SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.